Results 21 to 30 of about 25,643 (173)

COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ORIGINAL AND GENERIC ENALAPRIL IN THE ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION

open access: yesРациональная фармакотерапия в кардиологии, 2015
Aim. To study the pharmacokinetic, pharmacodynamic and pharmacoeconomic parameters of the original and generic enalaprils in the treatment of the elderly patients with hypertension (HT). Material and Methods.
O. P. Bobrova, M. M. Petrova
doaj   +3 more sources

Study of dissolution profiles of Аmlodipine tablets with enalapril

open access: yesUkrainian Scientific Medical Youth Journal, 2022
quality assurance in the production of medicines is a comprehensive concept. The quality of medicines must be guaranteed at all stages of production - from development, research and production to implementation and optimal use.
Nataliia Behei, Oksana Tryhubchak
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

COMPARATIVE EFFICACY OF ACE INHIBITORS (RAMIPRIL VS ENALAPRIL) IN TREATMENT OF CHRONIC HEART FAILURE IN WOMEN

open access: yesРациональная фармакотерапия в кардиологии, 2016
Aim. To compare clinical and haemodynamic efficacy of ramipril vs enalapril in women with chronic heart failure (CHF).Material and methods. 60 women with non valvular CHF were included in the study.
S. N. Tereshchenko   +3 more
doaj   +1 more source

Lowering serum homocysteine in H-type hypertensive patients with atrial fibrillation after radiofrequency catheter ablation to prevent atrial fibrillation recurrence

open access: yesFrontiers in Nutrition, 2022
BackgroundPrior investigation revealed that elevated serum total homocysteine (tHcy) are strongly correlated with atrial fibrillation (AF) recurrence. Herein, the goal of this study was to elucidate whether folic acid (FA) treatment reduced AF recurrence
Youzheng Dong   +13 more
doaj   +1 more source

Two strategies for arterial hypertension treatment in patients with secondary chronic pyelonephritis

open access: yesКардиоваскулярная терапия и профилактика, 2011
Aim. To compare the antihypertensive effectiveness, cardio- and nephroprotection, and metabolic effects of the combinations “enalapril + indapamide” vs. “enalapril + nifedipine slow release (SR)” in patients with arterial hypertension (AH) and secondary ...
M. E. Statsenko, M. V. Derevyanchenko
doaj   +1 more source

Aliskiren, enalapril, or aliskiren and enalapril in heart failure [PDF]

open access: yes, 2016
BACKGROUND Among patients with chronic heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown.
Ali, M. Atif   +56 more
core   +2 more sources

A Comparative Study of the Safety and Efficacy of Amlodipine and Enalapril when Prescribed as Monotherapy in Patients with Isolated Systolic Hypertension

open access: yesJournal of Nobel Medical College, 2023
Background: Most elderly patients with high blood pressure have isolated systolic hypertension. Enalapril and amlodipine are respectively the most commonly prescribed ACE inhibitors and calcium channel blockers in Nepal. The goal of the current study was
Rajesh Yadav, Rekha Shah
doaj   +1 more source

A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers

open access: yesJournal of Analytical Methods in Chemistry, 2017
Enalapril is an angiotensin-converting enzyme inhibitor used for treatment of hypertension and chronic heart disease. Enalaprilat is its active metabolite responsible for the activity.
Wael Abu Dayyih   +6 more
doaj   +1 more source

Treatment optimization of angiotensin converting enzyme inhibitors and associated factors in Ayder Comprehensive Specialized Hospital: a cross-sectional study

open access: yesBMC Research Notes, 2018
Background Angiotensin-converting enzyme inhibitors have morbidity and mortality benefits in heart failure. Failure to optimize treatment using these medications increases hospitalizations, worsens signs and symptoms of heart failure, and reduces the ...
Tesfay Mehari Atey   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy